T
Timothy J. Molloy
Researcher at University of New South Wales
Publications - 43
Citations - 2444
Timothy J. Molloy is an academic researcher from University of New South Wales. The author has contributed to research in topics: Breast cancer & Tendon. The author has an hindex of 23, co-authored 42 publications receiving 2151 citations. Previous affiliations of Timothy J. Molloy include St. Vincent's Health System & Netherlands Cancer Institute.
Papers
More filters
Journal ArticleDOI
The Roles of Growth Factors in Tendon and Ligament Healing
TL;DR: This review covers some of the recent investigations into the roles of five growth factors whose activities have been best characterised during tendon healing: insulin-like growth factor-I (IGF-I), transforming growth factor β (TGFβ), vascular endothelial growthFactor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor ($FGF).
Journal ArticleDOI
Cytokines and apoptosis in supraspinatus tendinopathy
TL;DR: It is suggested that pro-inflammatory cytokines may play a role in tendinopathy and may provide a target for preventing tendinopathies.
Journal ArticleDOI
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
Angela Chou,Danielle Froio,Adnan Nagrial,Adnan Nagrial,Ashleigh Parkin,Kendelle J. Murphy,Venessa T. Chin,Dalia Wohl,Angela Steinmann,Rhys Stark,Alison Drury,Stacey N. Walters,Claire Vennin,Andrew Burgess,Andrew Burgess,Mark Pinese,Lorraine A. Chantrill,Lorraine A. Chantrill,Mark J. Cowley,Timothy J. Molloy,Nicola Waddell,Amber L. Johns,Sean M. Grimmond,David K. Chang,Andrew V. Biankin,Owen J. Sansom,Jennifer P. Morton,Shane T. Grey,Shane T. Grey,Thomas R. Cox,John Turchini,Jaswinder S. Samra,Stephen Clarke,Paul Timpson,Paul Timpson,Anthony J. Gill,Marina Pajic,Marina Pajic +37 more
TL;DR: Subtype-specific in vivo efficacy of PD-0332991-based therapy was for the first time observed at multiple stages of PDA progression: primary tumour growth, recurrence (second-line therapy) and metastatic setting and may potentially be guided by a simple biomarker (RB protein).
Journal ArticleDOI
miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense.
Marina Pajic,Marina Pajic,Danielle Froio,Sheridan Daly,Louise Doculara,Ewan K.A. Millar,Ewan K.A. Millar,Ewan K.A. Millar,Peter Graham,Alison Drury,Angela Steinmann,Charles E. de Bock,Alice Boulghourjian,Anaiis Zaratzian,Susan Carroll,Joanne Toohey,Sandra A O'Toole,Sandra A O'Toole,Sandra A O'Toole,Adrian L. Harris,Francesca M. Buffa,Harriet E. Gee,Harriet E. Gee,Georgina E Hollway,Georgina E Hollway,Timothy J. Molloy +25 more
TL;DR: It is shown that miR-139-5p is a potent modulator of radiotherapy response in breast cancer via its regulation of genes involved in multiple DNA repair and reactive oxygen species defense pathways.
Journal ArticleDOI
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
Timothy J. Molloy,Astrid Bosma,Lars Oliver Baumbusch,Lars Oliver Baumbusch,Marit Synnestvedt,Elin Borgen,Hege G. Russnes,Ellen Schlichting,Laura J. van't Veer,Bjørn Naume,Bjørn Naume +10 more
TL;DR: These results support the use of CTC analysis in early breast cancer to generate clinically useful prognostic information and indicated different relevance within biologically dissimilar breast cancer subtypes.